These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 35914727)
1. Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients. Kimura M; Ferreira VH; Kothari S; Pasic I; Mattsson JI; Kulasingam V; Humar A; Mah A; Delisle JS; Ierullo M; Majchrzak-Kita B; Kumar D; Hosseini-Moghaddam SM Transplant Cell Ther; 2022 Oct; 28(10):706.e1-706.e10. PubMed ID: 35914727 [TBL] [Abstract][Full Text] [Related]
2. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study. Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M Front Immunol; 2023; 14():1169666. PubMed ID: 37153556 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Safety of Booster SARS-CoV-2 mRNA Vaccine Dose in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Mittal A; Solera JT; Ferreira VH; Kothari S; Kimura M; Pasic I; Mattsson JI; Humar A; Kulasingam V; Ierullo M; Kumar D; Hosseini-Moghaddam SM Transplant Cell Ther; 2023 Nov; 29(11):706.e1-706.e7. PubMed ID: 37582470 [TBL] [Abstract][Full Text] [Related]
4. Risk factors and characteristics influencing humoral response to COVID-19 vaccination in patients after allogeneic stem cell transplantation. Hütter-Krönke ML; Neagoie A; Blau IW; Wais V; Vuong L; Gantner A; Ahn J; Penack O; Schnell J; Nogai KA; Eberspächer B; Saadati M; Benner A; Bullinger L; Döhner H; Bunjes D; Sala E Front Immunol; 2023; 14():1174289. PubMed ID: 37207199 [TBL] [Abstract][Full Text] [Related]
5. Specific immune response to mRNA vaccines against COVID-19 in patients receiving allogeneic stem cell transplantation for myeloid malignancy was altered by immunosuppressive therapy. Macková J; Hainz P; Kryštofová J; Roubalová K; Šťastná-Marková M; Vaníková Š; Musil J; Vydra J; Němečková Š Leuk Res; 2023 Jul; 130():107314. PubMed ID: 37216792 [TBL] [Abstract][Full Text] [Related]
6. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
7. Antibody, cell-mediated response and infection susceptibility in allogeneic hematopoietic stem cell recipients after COVID-19 mRNA vaccination. Pizzano U; Facchin G; Marcon C; Fabris M; Battista ML; Cerno M; Geromin A; Pucillo M; Petruzzellis G; Vianello G; Battaglia G; Peressutti R; Grillone L; Tascini C; Curcio F; Fanin R; Patriarca F Transpl Infect Dis; 2023 Apr; 25(2):e14003. PubMed ID: 36748718 [TBL] [Abstract][Full Text] [Related]
8. B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Jullien M; Le Bourgeois A; Coste-Burel M; Peterlin P; Garnier A; Rimbert M; Imbert BM; Le Gouill S; Moreau P; Mahe B; Dubruille V; Blin N; Lok A; Touzeau C; Gastinne T; Tessoulin B; Vantyghem S; Béné MC; Guillaume T; Chevallier P Transplant Cell Ther; 2022 May; 28(5):279.e1-279.e4. PubMed ID: 35218998 [TBL] [Abstract][Full Text] [Related]
9. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia. Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554 [TBL] [Abstract][Full Text] [Related]
14. Cellular and humoral immunogenicity against SARS-CoV-2 vaccination or infection is associated with the memory phenotype of T- and B-lymphocytes in adult allogeneic hematopoietic cell transplant recipients. Konuma T; Hamatani-Asakura M; Nagai E; Adachi E; Kato S; Isobe M; Monna-Oiwa M; Takahashi S; Yotsuyanagi H; Nannya Y Int J Hematol; 2024 Aug; 120(2):229-240. PubMed ID: 38842630 [TBL] [Abstract][Full Text] [Related]
15. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients. Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N Front Immunol; 2022; 13():1050211. PubMed ID: 36532067 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177 [TBL] [Abstract][Full Text] [Related]
17. Strong SARS-CoV-2 T-Cell Responses after One or Two COVID-19 Vaccine Boosters in Allogeneic Hematopoietic Stem Cell Recipients. Clémenceau B; Le Bourgeois A; Guillaume T; Coste-Burel M; Peterlin P; Garnier A; Jullien M; Ollier J; Grain A; Béné MC; Chevallier P Cells; 2022 Sep; 11(19):. PubMed ID: 36230971 [TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study. Alexander JL; Liu Z; Muñoz Sandoval D; Reynolds C; Ibraheim H; Anandabaskaran S; Saifuddin A; Castro Seoane R; Anand N; Nice R; Bewshea C; D'Mello A; Constable L; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HRT; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Goodhand JR; Hart AL; Lees CW; Boyton RJ; Kennedy NA; Ahmad T; Powell N; Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1005-1015. PubMed ID: 36088954 [TBL] [Abstract][Full Text] [Related]
20. Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study. Wang H; Gan M; Wu B; Zeng R; Wang Z; Xu J; Li J; Zhang Y; Cao J; Chen L; Di D; Peng S; Lei J; Zhao Y; Song X; Yuan T; Zhou T; Liu Q; Yi J; Wang X; Cai H; Lei Y; Wen Y; Li W; Chen Q; Wang Y; Long P; Yuan Y; Wang C; Pan A; Wang Q; Gong R; Fan X; Wu T; Liu L J Med Virol; 2023 Jan; 95(1):e28380. PubMed ID: 36478357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]